Literature DB >> 34478584

Protocols for multi-site trials using hyperpolarized 129 Xe MRI for imaging of ventilation, alveolar-airspace size, and gas exchange: A position paper from the 129 Xe MRI clinical trials consortium.

Peter J Niedbalski1, Chase S Hall1, Mario Castro1, Rachel L Eddy2,3, Jonathan H Rayment4, Sarah Svenningsen5,6, Grace Parraga7, Brandon Zanette8, Giles E Santyr8,9, Robert P Thomen10, Neil J Stewart11, Guilhem J Collier11, Ho-Fung Chan11, Jim M Wild11, Sean B Fain12, G Wilson Miller13, Jaime F Mata13, John P Mugler13, Bastiaan Driehuys14, Matthew M Willmering15, Zackary I Cleveland15,16, Jason C Woods15,16.   

Abstract

Hyperpolarized (HP) 129 Xe MRI uniquely images pulmonary ventilation, gas exchange, and terminal airway morphology rapidly and safely, providing novel information not possible using conventional imaging modalities or pulmonary function tests. As such, there is mounting interest in expanding the use of biomarkers derived from HP 129 Xe MRI as outcome measures in multi-site clinical trials across a range of pulmonary disorders. Until recently, HP 129 Xe MRI techniques have been developed largely independently at a limited number of academic centers, without harmonizing acquisition strategies. To promote uniformity and adoption of HP 129 Xe MRI more widely in translational research, multi-site trials, and ultimately clinical practice, this position paper from the 129 Xe MRI Clinical Trials Consortium (https://cpir.cchmc.org/XeMRICTC) recommends standard protocols to harmonize methods for image acquisition in HP 129 Xe MRI. Recommendations are described for the most common HP gas MRI techniques-calibration, ventilation, alveolar-airspace size, and gas exchange-across MRI scanner manufacturers most used for this application. Moreover, recommendations are described for 129 Xe dose volumes and breath-hold standardization to further foster consistency of imaging studies. The intention is that sites with HP 129 Xe MRI capabilities can readily implement these methods to obtain consistent high-quality images that provide regional insight into lung structure and function. While this document represents consensus at a snapshot in time, a roadmap for technical developments is provided that will further increase image quality and efficiency. These standardized dosing and imaging protocols will facilitate the wider adoption of HP 129 Xe MRI for multi-site pulmonary research.
© 2021 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  diffusion; gas exchange; hyperpolarized 129Xe; protocol standardization; ventilation

Mesh:

Substances:

Year:  2021        PMID: 34478584     DOI: 10.1002/mrm.28985

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  4 in total

1.  Pediatric 129 Xe Gas-Transfer MRI-Feasibility and Applicability.

Authors:  Matthew M Willmering; Laura L Walkup; Peter J Niedbalski; Hui Wang; Ziyi Wang; Erik B Hysinger; Kasiani C Myers; Christopher T Towe; Bastiaan Driehuys; Zackary I Cleveland; Jason C Woods
Journal:  J Magn Reson Imaging       Date:  2022-03-04       Impact factor: 5.119

2.  Bias field correction in hyperpolarized 129 Xe ventilation MRI using templates derived by RF-depolarization mapping.

Authors:  Junlan Lu; Ziyi Wang; Elianna Bier; Suphachart Leewiwatwong; David Mummy; Bastiaan Driehuys
Journal:  Magn Reson Med       Date:  2022-05-04       Impact factor: 3.737

3.  Noninvasive diagnosis of pulmonary hypertension with hyperpolarised 129Xe magnetic resonance imaging and spectroscopy.

Authors:  Elianna A Bier; Fawaz Alenezi; Junlan Lu; Ziyi Wang; Joseph G Mammarappallil; Bryan O'Sullivan-Murphy; Alaattin Erkanli; Bastiaan Driehuys; Sudarshan Rajagopal
Journal:  ERJ Open Res       Date:  2022-05-16

4.  Standalone portable xenon-129 hyperpolariser for multicentre clinical magnetic resonance imaging of the lungs.

Authors:  Graham Norquay; Guilhem J Collier; Oliver I Rodgers; Andrew B Gill; Nicholas J Screaton; Jim Wild
Journal:  Br J Radiol       Date:  2022-01-31       Impact factor: 3.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.